Source:http://linkedlifedata.com/resource/pubmed/id/16934779
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2006-10-9
|
pubmed:abstractText |
The etiology of Parkinson's disease remains poorly understood, and current treatment options do not slow disease progression. Recently, chemical (thrombin) preconditioning (TPC) was found to be protective in a 6-hydroxydopamine (6-OHDA) model of the disease. It is important to understand the mechanisms behind these thrombin-induced protective effects. The current study was conducted in the rat to determine whether the protective effects of TPC are mediated via activation of protease-activated receptors (PARs). Preconditioning with specific local infusion of agonist peptides for PAR-1 and PAR-4 3 days before unilateral 6-OHDA administration (10 microg into the medial forebrain bundle) was tested. In addition, co-administration of a PAR-1 antagonist with TPC was examined. In a neurobehavioral assessment battery, PAR-1 agonist preconditioning provided protection in a vibrissae-elicited forelimb placing test, a forelimb-use asymmetry test, and a corner turn test. In addition, inclusion of a PAR-1 antagonist prevented the protective effects elicited by TPC. In contrast to the effects of the PAR-1 agonist, PAR-4 agonist preconditioning afforded no such protection. Indeed, in a lower-dose model of 6-OHDA (5 microg), PAR-4 preconditioning significantly increased behavioral deficits. These results indicate that the protective effects of TPC in this model are mediated through PAR-1 activation. Neither the effects of PAR-1 nor TPC on later 6-OHDA-induced behavioral deficits appeared to be mediated through (DA) content sparing. Further mechanistic studies on the actions of PAR-1 and PAR-4 as detrimental in experimental models of Parkinson's disease are warranted.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/3,4-Dihydroxyphenylacetic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Catecholamines,
http://linkedlifedata.com/resource/pubmed/chemical/Homovanillic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Oxidopamine,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, PAR-1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Thrombin,
http://linkedlifedata.com/resource/pubmed/chemical/Sympatholytics,
http://linkedlifedata.com/resource/pubmed/chemical/Thrombin,
http://linkedlifedata.com/resource/pubmed/chemical/protease-activated receptor 4
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0006-8993
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
20
|
pubmed:volume |
1116
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
177-86
|
pubmed:dateRevised |
2007-12-3
|
pubmed:meshHeading |
pubmed-meshheading:16934779-3,4-Dihydroxyphenylacetic Acid,
pubmed-meshheading:16934779-Animals,
pubmed-meshheading:16934779-Behavior, Animal,
pubmed-meshheading:16934779-Biotransformation,
pubmed-meshheading:16934779-Catecholamines,
pubmed-meshheading:16934779-Forelimb,
pubmed-meshheading:16934779-Homovanillic Acid,
pubmed-meshheading:16934779-Male,
pubmed-meshheading:16934779-Oxidopamine,
pubmed-meshheading:16934779-Parkinson Disease, Secondary,
pubmed-meshheading:16934779-Rats,
pubmed-meshheading:16934779-Rats, Sprague-Dawley,
pubmed-meshheading:16934779-Receptor, PAR-1,
pubmed-meshheading:16934779-Receptors, Thrombin,
pubmed-meshheading:16934779-Sympatholytics,
pubmed-meshheading:16934779-Thrombin,
pubmed-meshheading:16934779-Vibrissae
|
pubmed:year |
2006
|
pubmed:articleTitle |
Protease-activated receptor-1 mediates protection elicited by thrombin preconditioning in a rat 6-hydroxydopamine model of Parkinson's disease.
|
pubmed:affiliation |
Department of Neurosurgery, University of Michigan, Ann Arbor, MI 48109, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|